Protein Kinases in Hematological Disorders.

Area of Science:

• Molecular Biology
• Cellular Signaling
• Hematology

Background:

• Cell signaling regulates cellular activities, and disruptions can lead to diseases like cancer.
• Protein kinases (PKs) are key mediators of cell signal transduction, with serine/threonine and tyrosine kinases being the main groups.
• PKs are implicated in the pathobiology of hematologic neoplastic disorders, such as those involving JAK2 mutations.

Purpose of the Study:

• To review the functions of protein kinases in the pathobiology of hematologic neoplastic disorders.
• To explore the interactions between local bone marrow renin-angiotensin system (RAS) and protein kinases.

Main Methods:

• Literature review of protein kinases and their roles in hematologic cancers.
• Analysis of signaling pathways involving protein kinases and the renin-angiotensin system.
• Discussion of existing protein kinase inhibitor drugs in clinical hematology.

Main Results:

• Protein kinases play significant roles in the development and progression of hematologic neoplastic disorders.
• Specific mutations in PKs, like JAK2V617F, are linked to diseases such as polycythemia vera and essential thrombocytosis.
• Interactions between the local bone marrow RAS and PKs, such as the ACE2-ang(1-7)-Mas axis inhibiting p38 MAPK/NF-κB, are identified.

Conclusions:

• Protein kinases are critical targets for understanding and treating hematologic neoplastic disorders.
• The local bone marrow RAS may influence PK activity, suggesting potential therapeutic avenues.
• Targeted protein kinase inhibitors are valuable in managing hematologic malignancies.